More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.00B
EPS
-0.89
P/E ratio
--
Price to sales
4.71
Dividend yield
--
Beta
1.893239
Previous close
$19.89
Today's open
$19.63
Day's range
$19.49 - $20.06
52 week range
$7.61 - $21.78
show more
CEO
Jerrell W. Shelton
Employees
738
Headquarters
Brentwood, TN
Exchange
NASDAQ Capital Market
Shares outstanding
50700429
Issue type
Common Stock
Industrials
Transportation
Cryoport Needs To Chill Down (Downgrade)
Cryoport, Inc. is downgraded from Hold to Sell due to valuation concerns despite strong revenue growth. CYRX's balance sheet improved after the CRYOPDP sale, with net cash of $204.8 million, but profitability remains elusive. Revenue outperformed forecasts, driven by Life Sciences Services and commercial cell/gene therapy, yet net losses widened and margins remain weak.
Seeking Alpha • Nov 9, 2026

CryoPort Q3 Earnings Call Highlights
CryoPort NASDAQ: CYRX raised its full-year 2026 revenue outlook after reporting third-quarter revenue growth of 14%, supported by demand for its cell and gene therapy services and cryogenic products.
MarketBeat • Nov 6, 2026

Cryoport, Inc. (CYRX) Q3 2026 Earnings Call Transcript
Cryoport, Inc. ( CYRX ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Jerrell Shelton - Chairman, President & CEO Robert Stefanovich - Senior VP, CFO, Treasurer & Chief Administrative Officer Thomas Heinzen - Vice President of Corporate Development & Investor Relations Mark W. Sawicki - Senior VP & Chief Scientific Officer Conference Call Participants Todd Fromer - Kanan, Corbin, Schupak & Aronow, Inc. Philip Seunghwa Song - Leerink Partners LLC, Research Division Steven Etoch - Stephens Inc., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Richard Baldry - ROTH Capital Partners, LLC, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division David Larsen - BTIG, LLC, Research Division Matthew Stanton - Jefferies LLC, Research Division Presentation Operator Good afternoon, and welcome to Cryoport's Third Quarter 2026 Earnings Call.
Seeking Alpha • Nov 6, 2026

Cryoport Reports Third Quarter 2026 Financial Results
Third quarter revenue grew 14% year-over-year to $50.2 million Commercial Cell and Gene Therapy revenue increased 20% year-over-year Supporting a record 788 global clinical trials and 23 commercially approved cell and gene therapies as of September 30, 2026 Raises full-year 2026 revenue guidance to $197 million - $199 million NASHVILLE, Tenn., Nov. 5, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2026.
PRNewsWire • Nov 5, 2026

CryoPort, Inc. (CYRX) Reports Q3 Loss, Tops Revenue Estimates
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
Zacks Investment Research • Nov 5, 2026

Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells
We remain encouraged by the operational performance of the Micro cap companies held in portfolios. TWST shares surged as a strong fiscal 3Q highlighted accelerating demand across several of the company's end markets. TKNO management responded to the stronger first half by substantially raising its full-year revenue outlook.
Seeking Alpha • Oct 30, 2026

Cryoport to Report Third Quarter 2026 Financial Results on November 5, 2026
NASHVILLE, Tenn., Oct. 22, 2026 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the third quarter ended September 30, 2026 on Thursday, November 5, 2026 after U.S. markets close.
PRNewsWire • Oct 22, 2026

Is CryoPort (CYRX) Outperforming Other Medical Stocks This Year?
Here is how CryoPort, Inc. (CYRX) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.
Zacks Investment Research • Oct 1, 2026

Cryoport: Strong Pipeline Of Cell And Gene Therapy Approvals
Cryoport, Inc., rated BUY, is up 82% YTD, driven by robust cell and gene therapy (CGT) commercialization and pipeline momentum. CYRX returned to adjusted EBITDA profitability in 2Q26, with strong Life Science Services growth and positive operating cash flow of $8 million TTM. Management expects 5 new CGT commercial approvals in 2026, supported by a 15% YoY increase in the Phase 3 trial pipeline to 94 trials.
Seeking Alpha • Sep 25, 2026

CryoPort (CYRX) Upgraded to Buy: Here's Why
CryoPort (CYRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Investment Research • Aug 11, 2026

¹ Disclosures

Open an M1 investment account to buy and sell CryoPort Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.